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Abstract 
Background: We aimed to investigate whether visceral adiposity could modify the impact of blood pressure on arte-
rial stiffness and albuminuria in patients with type 2 diabetes.
Methods: This cross-sectional study examines the interaction of visceral adiposity with increased blood pressure 
on arterial stiffness and albuminuria. 638 patients with type 2 diabetes (mean age 64 ± 12 years; 40 % female) were 
enrolled. Visceral fat area (VFA, cm2) was assessed by a dual-impedance analyzer, whereby patients were divided into 
those with VFA < 100 (N = 341) and those with VFA ≥ 100 (N = 297). Albuminuria was measured in a single 24-h urine 
collection (UAE, mg/day) and brachial-ankle pulse wave velocity (ba-PWV, cm/s) was used for the assessment of arte-
rial stiffening. Linear regression analyses were used to investigate the association of systolic blood pressure (SBP) and 
VFA with UAE and baPWV.
Results: Patients with VFA ≥ 100 were significantly younger, had higher SBP, HbA1c, triglycerides, UAE, alanine ami-
notransferase, C-reactive protein and lower high-density lipoprotein and shorter duration of diabetes than those with 
VFA < 100. SBP was significantly and almost equivalently associated with ba-PWV both in VFA < 100 (standardized 
β 0.224, p = 0.001) and VFA ≥ 100 (standardized β 0.196, p = 0.004) patients in the multivariate regression analysis 
adjusting for covariates including age, gender, HbA1c, diabetic complications and the use of insulin and anti-hyper-
tensive agents. By contrast, the association of SBP with UAE was stronger in patients with VFA ≥ 100 (standardized β 
0.263, p = 0.001) than that in patients with VFA < 100 (standardized β 0.140, p = 0.080) in the multivariate regression 
model. In the whole cohort, the significant interaction between SBP and VFA on UAE (standardized β 0.172, p = 0.040) 
but not on ba-PWV (standardized β −0.008, p = 0.916) was observed.
Conclusions: The effect of increased blood pressure on arterial stiffness is almost similar in type 2 diabetic patients 
with both low and high visceral adiposity, while its association with albuminuria is stronger in the latter.
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Background
Blood pressure is a strong risk factor for cardiovascular 
disease (CVD) [1, 2] and chronic kidney disease (CKD) 
[3–5]. Among patients with diabetes, hypertension is 
associated with the incidence of CVD and CKD as well 
[6–9]. The reduction of blood pressure could reduce the 
risks both for CVD and CKD.
Obesity, especially increased visceral adiposity is a 
major cause of hypertension, accounting for 65–75 % of 
the risk for human essential hypertension [10]. In addi-
tion, obesity has been reported to be associated with 
various cardio-metabolic risks including insulin resist-
ance and dyslipidemia, and also be directly associated 
with CVD [11–14]. Furthermore, abdominal obesity is 
a strong risk factor for CKD both in general population 
and patients with diabetes [15, 16]. Therefore, abdominal 
adiposity is thought to be an important determinant that 
can account for the association of cardio-metabolic risks 
with CVD and CKD.
Regarding the association between blood pressure 
and CVD, the impact of elevated blood pressure on 
CVD events has been reported to be stronger among 
people without obesity than those with [17–19]. Also, 
it has been suggested that normal-weight patients 
with essential hypertension have increased arterial 
stiffness [20] and systemic vascular resistance. We 
recently reported that increased visceral adiposity 
with normal weight is strongly associated with car-
dio-metabolic risks and arterial stiffness in patients 
with type 2 diabetes [21]. These studies imply that 
visceral adiposity could modify the impact of blood 
pressure on CVD; however, it is uncertain whether 
increased blood pressure could more strongly affect 
arterial stiffening in people with low visceral adipos-
ity than in those with high visceral adiposity. On the 
other hand, among obese people, especially those with 
high visceral adiposity, intra-renal renin-angiotensin-
aldosterone system is activated [22–24], leading to 
the glomerular hyperfiltration at the early stage of 
obesity-hypertension. Hyperglycemia also induces 
renal damage directly or through hemodynamic modi-
fications including glomerular hyperfiltration [25]. 
Therefore, it is possible that increase in systemic 
blood pressure could more strongly affect the renal 
hemodynamics in obese, especially in obese patients 
with diabetes, than in non-obese people, resulting in 
more severe renal manifestations such as increased 
albuminuria and decreased glomerular filtration rate 
(GFR). Taken together, we conducted this cross-sec-
tional study to investigate the interaction of visceral 
adiposity with blood pressure on the increased risk 




Patients with type 2 diabetes who admitted to Tokyo 
Medical and Dental University Hospital for the purpose 
of glycemic control and/or evaluation of diabetic compli-
cations participated in this cross-sectional study. Patients 
were eligible, if they were aged ≥20  years, and patients 
who measured both brachia-ankle pulse wave velocity 
(ba-PWV) and visceral fat area (VFA) and subcutaneous 
fat area (SFA) by a dual bioelectrical impedance analyzer 
were enrolled. Patients with severe renal impairment 
(estimated glomerular filtration rate [eGFR]  <15  mL/
min/1.73  m2 or undergoing renal replacement therapy), 
pregnant women, and those with infectious or malig-
nant diseases were excluded. Type 2 diabetes was diag-
nosed according to the criteria of the Japan Diabetes 
Society (JDS) [26]. As shown in Fig. 1, 638 patients were 
finally enrolled in this study. This study complies with the 
principles laid by Declaration of Helsinki and has been 
approved by the ethical committee of Tokyo Medical and 
Dental University (No. 1924).
Clinical and biochemical analysis
Standardized questionnaires were used to obtain infor-
mation on smoking, medication and past history. Smok-
ing history was classified as either current smoker or 
non-smoker. CVD was defined as the presence of a 
previous stroke, myocardial infarction, coronary revas-
cularization procedure. Blood pressure was measured 
in the sitting position after at least 5 min rest, using an 
electronic sphygmomanometer (ES-H55, Terumo Inc., 
Subjects with type 2 diabetes (N = 738)
Exclusion
if, severe renal impairment (N = 4)
if, pregnant women (N = 3)
if, history of malignancy (N = 52)
if, active infectious diseases (N = 5)
Subjects with brachial-ankle pulse wave velocity and 
visceral fat area scanning (N = 702)
Final study sample after exclusion
(N = 638)
Fig. 1 Flowchart of patient recruitment to the study
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Tokyo, Japan). HbA1c was measured by the latex agglu-
tination method. HbA1c levels were expressed in accord-
ance with the National Glycohemoglobin Standardization 
Programs recommended by the Japanese Diabetes Soci-
ety [26]. Urinary albumin (UAE) and creatinine excretion 
were measured by the turbidimetric immunoassay and 
enzymatic method, respectively, in a single 24-h urine 
collection. GFR was estimated using the following equa-
tion for the Japanese, as proposed by the Japanese Society 
of Nephrology [27]; GFR =  194 ×  SCr−1.094 ×  age−0.287 
[(if female) × 0.739], where SCr stands for serum creati-
nine in mg/dl, measured by an enzymatic method. Coef-
ficient of variation of R–R intervals (CV-RR) was used 
for the assessment of diabetic neuropathy. BMI was cal-
culated as weight divided by the square of height (kg/
m2). VFA and SFA were measured at the level of umbili-
cus by dual bioelectrical impedance analyzer (DUALS-
CAN, Omron Healthcare Co., Kyoto, Japan). Patients 
were divided into those with VFA < 100 cm2 (low-V) and 
those with VFA ≥ 100 cm2 (high-V). Brachial-ankle pulse 
wave velocity (ba-PWV) was measured using a volume-
plethysmographic apparatus (BP-203RPE II form PWV/
ABI, Omron Healthcare Co., Kyoto, Japan), with subjects 
in the supine position after at least 5 min of rest [28, 29]. 
The ba-PWV was calculated as reported previously [30]. 
We simultaneously measured ba-PWV on both the right 
and left sides and the averaged values from each individ-
ual were subjected to statistical analysis.
Statistical analysis
Statistical analysis was performed using programs availa-
ble in the SPSS version 21.0 statistical package (SPSS Inc., 
Chicago, IL, USA). Data are presented as mean  ±  SD, 
median with interquartile range (IQR), or percent as 
appropriate according to data distribution. Normal-
ity was tested by the Kolmogorov–Smirnov test. Differ-
ences between low-V and high-V patients were tested 
with a t test or Mann–Whitney U test for continuous 
variables and Chi square test for categorical variables. 
Linear regression analyses were used to investigate the 
association of SBP and VFA with ba-PWV and UAE. We 
determined the linear relationship and multicollinearity 
for regression assumptions. We removed one variable if 
a strong correlation (coefficient of correlation >0.8) was 
observed between the two independent variables. In 
order to check the multicollinearity, we evaluated vari-
ance infiltration factors. If multicollinearity was found 
in the data, one variable was removed from the multi-
variate regression analysis. The following covariates were 
incorporated into the analysis with a stepwise procedure; 
duration of diabetes, smoking status, triglycerides, high-
density lipoprotein (HDL) cholesterol, low-density lipo-
protein (LDL) cholesterol, HbA1c, eGFR, log CRP and 
the usage of insulin, calcium channel blockers (CCB), 
angiotensin receptor blockers (ARB), statins and anti-
platelet agents. Age and gender were forced into the 
model. The interaction between SBP and VFA was also 
investigated in the multiple linear regression analyses. 
Differences were considered to be statistically significant 
at p value less than 0.05.
Results
Clinical characteristics of patients with low‑V and high‑V
Among 638 patients, 341 and 297 were classified as low-V 
and high-V patients. As shown in Table 1, high-V patients 
were significantly younger, had significantly higher SBP 
and DBP, lower HDL-C, higher triglycerides levels and 
a shorter duration of diabetes than the low-V patients. 
Urinary C-peptide and UAE levels in high-V patients 
were significantly higher than those in low-V patients. 
BMI, WC, VFA and SFA levels in high-V patients were 
significantly higher than in those with low-V. The high-
V patients were more frequently receiving CCBs, ARBs 
and statin therapy and were less likely to receive insulin 
than low-V patients. baPWV in high-V patients was sig-
nificantly lower than that in low-V patients.
Association between SBP and baPWV according to VFA 
categories
Table 2 shows the linear regression analyses to investigate 
the association between SBP and ba-PWV in patients 
with low-V and those with high-V. In the univariate 
model, SBP was significantly and equivalently associated 
with ba-PWV. After adjusting for age and gender, the sta-
tistical significance of SBP with ba-PWV was unchanged 
both in patients with low-V and those with high-V. In the 
multivariate model including covariates such as eGFR 
and anti-hypertensive agents, the association of SBP 
with ba-PWV remained significant regardless of vis-
ceral adiposity (standardized β 0.224, p = 0.001 in low-V 
and standardized β 0.196, p = 0.004 in high-V). Among 
patients with high-V, SFA was inversely associated with 
ba-PWV (standardized β −0.199, p = 0.007). eGFR was a 
significant covariate regardless of visceral adiposity.
Association between SBP and UAE according to VFA 
categories
Table  3 shows the association between SBP and UAE 
according to VFA categories among patients with type 2 
diabetes. In the univariate model, SBP was significantly 
associated with UAE both in patients with low-V and 
those with high-V. The association of SBP with UAE was 
unchanged in age- and gender-adjusted model regardless 
of visceral adiposity (standardized β 0.205, p = 0.001 in 
patients with low-V and standardized β 0.290, p < 0.001 
in patients with high-V). In the multivariate model 
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adjusting for covariates including age, gender, diabetic 
complications such as neuropathy and retinopathy and 
HbA1c level, SBP remained significantly associated with 
UAE in patients with high-V (standardized β 0.263, 
p = 0.001); whereas, its association with UAE was attenu-
ated in those patients with low-V (standardized β 0.140, 
p = 0.080).
Interaction between SBP and VFA accounting for the risk 
of arterial stiffening and albuminuria
Table 4 shows the multivariate linear regression analyses 
to investigate whether binary interaction between SBP 
and VFA could account for the risks of arterial stiffen-
ing and albuminuria in the whole cohort. The significant 
interaction between SBP and VFA was observed in the 
model where UAE was used for a dependent variable; 
whereas, no significant interaction of SBP with VFA was 
found as for ba-PWV.
Discussion
Both increased arterial stiffness and albuminuria are 
strong predictors for mortality, CVD and CKD in patients 
with diabetes [31–36]. Therefore, it is important to eluci-
date the high risk groups both for increased arterial stiff-
ness and albuminuria among diabetic patients. This study 
clearly demonstrates that increased SBP can equivalently 
account for the risk for arterial stiffening regardless of 
visceral adiposity; whereas, the impact of SBP on albu-
minuria is stronger in diabetic patients with high visceral 
adiposity than those with low visceral adiposity.
Table 1 Clinical characteristics according to VFA levels
ALT alanine aminotransferase, ARB angiotensin receptor blocker, AST asparatate aminotransferase, baPWV brachial-ankle pulse wave velocity, CCB calcium channel 
blocker, CVD cardiovascular disease, CV-RR coefficient of variation of R–R intervals, DBP diastolic blood pressure, eGFR estimated glomerular filtration rate, HDL high-
density lipoprotein, LDL low-density lipoprotein, PDR proliferative diabetic retinopathy, SBP systolic blood pressure
VFA < 100 cm2 (N = 341) VFA ≥ 100 cm2 (N = 297) p values
Age (years) 66 ± 12 62 ± 13 <0.001
Gender (% male) 57 63 0.196
SBP (mmHg) 128 ± 20 132 ± 17 0.016
DBP (mmHg) 73 ± 12 78 ± 12 <0.001
HbA1c (mmol/mol) 71.6 ± 20.2 75.0 ± 19.5 0.029
HbA1c (%) 8.7 ± 1.8 9.0 ± 1.8
HDL-cholesterol (mmol/l) 1.32 ± 0.42 1.19 ± 0.31 <0.001
LDL-cholesterol (mmol/l) 2.87 (2.29–3.56) 2.79 (2.26–3.44) 0.515
Triglycerides (mmol/l) 1.31 (0.98–1.86) 1.61 (1.19–2.26) <0.001
Urinary C-peptide (μg/day) 42 (27–67) 60 (35–99) <0.001
Duration of diabetes (years) 12 (5–20) 10 (4–16) 0.044
Current smoker (%) 22 25 0.452
History of CVD 13 17 0.183
UAE (mg/day) 11 (7–26) 19 (10–58) 0.001
eGFR (ml/min/1.73 m2) 72.0 ± 23.3 71.5 ± 25.6 0.791
AST (U/l) 22 (17–28) 24 (19–41) <0.001
ALT (U/l) 19 (14–30) 28 (18–48) <0.001
C-reactive protein (mg/l) 0.80 (0.40–1.95) 1.60 (0.80–3.60) <0.001
PDR (%) 19 12 0.536
CV-RR (%) 3.3 (2.2–4.8) 3.6 (2.3–5.3) 0.109
ba-PWV (cm/s) 1711 (1459–1906) 1582 (1411–1785) 0.007
Body mass index (kg/m2) 23.5 ± 3.2 29.4 ± 4.4 <0.001
Waist circumference (cm) 86 ± 9 102 ± 11 <0.001
Visceral fat area (cm2) 74 (57–87) 133 (114–152) <0.001
Subcutaneous fat area (cm2) 144 (120–178) 236 (194–284) <0.001
Insulin (%) 75 61 0.002
CCBs (%) 29 39 0.023
ARBs (%) 35 53 <0.001
Statin (%) 42 52 0.050
Anti-platelets (%) 17 22 0.322
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Association of blood pressure and visceral adiposity 
with organ damage
Visceral adiposity has been reported to be associated 
with incident hypertension [37, 38] and albuminuria 
[39, 40]. More recently, we found that high visceral fat 
with low subcutaneous fat accumulation is an impor-
tant determinant of carotid atherosclerosis and high 
subcutaneous fat could be protective against athero-
sclerosis in patients with type 2 diabetes [41], and oth-
ers reported that subcutaneous fat thickness assessed 
by ultrasound is inversely associated with carotid ath-
erosclerosis in diabetic patients, particularly in men 
[42]. Moreover, visceral adiposity is strongly associ-
ated with the alteration of myocardial glucose uptake 
and its association further relates to type 2 diabetes 
[43]. These studies suggest that visceral and subcu-
taneous adiposities are directly associated not only 
cardio-metabolic risks but also target organ damage 
including heart and arterial wall injuries. We found 
in this study a stronger association of blood pressure 
with albuminuria in patients with high visceral adipos-
ity than those with low visceral adiposity, suggesting 
that visceral adiposity could modify the association of 
blood pressure at least with albuminuria in patients 
with type 2 diabetes.
Potential mechanisms regarding the interaction 
between blood pressure and adiposity on albuminuria
By which mechanisms are involved in the greater impact 
of elevated blood pressure on albuminuria in patients 
with high visceral adiposity than in those with low vis-
ceral adiposity? Sympathetic activity and local (renal) 
renin-angiotensin-aldosterone system could account for 
the association. Obesity increases sympathetic activity in 
the kidneys and skeletal muscle; however, cardiac sym-
pathetic activity may not be elevated [44–46]. Further-
more, excessive weight gain, especially visceral adiposity 
increases leptin level, promotes renal compression, acti-
vates renal renin-angiotensin-aldosterone system [47], all 
of which could impair renal-pressure natriuresis, increase 
glomerular pressure, leading to progression of albuminu-
ria. These observations could at least partly explain why 
elevated blood pressure is more strongly associated with 
albuminuria among patients with high visceral adiposity 
than among patients with low visceral adiposity.
Strengths and limitations
The strength of our study is that we directly measured 
VFA by a dual-impedance analyzer for the assessment 
Table 2 Linear regression analysis to investigate the asso-
ciation of blood pressure and visceral adiposity with arte-
rial stiffness in patients with type 2 diabetes
CCB calcium channel blocker, eGFR estimated glomerular filtration rate, SFA 












 Systolic blood 
pressure
0.172 0.001 0.253
 Age 0.426 <0.001 0.421




 Systolic blood 
pressure
0.224 0.001 0.196 0.004
 Age 0.430 <0.001 0.383 <0.001
 Gender (male 
versus female)
0.130 0.051 0.007 0.920
 eGFR −0.087 0.055 −0.199 0.042
 SFA NA 0.149 0.007
 CCB NA −0.155 0.031
Table 3 Linear regression analysis to investigate the asso-
ciation of blood pressure and visceral adiposity with albu-
minuria in patients with type 2 diabetes
CV-RR Coefficient of variation of RR intervals, eGFR estimated glomerular 








 Systolic blood 
pressure
0.203 0.001 0.280 <0.001
Age- and gender-adjusted
 Systolic blood 
pressure
0.205 0.001 0.290 <0.001
 Age 0.079 0.188 0.172 0.172
 Gender (male 
versus female)
0.074 0.219 0.087 0.087
Multivariate
 Systolic blood 
pressure
0.140 0.080 0.263 0.001
 Age −0.042 0.649 −0.090 0.236
 Gender (male 
versus female)
0.120 0.122 0.166 0.28
 eGFR −0.191 0.042 NA
 Insulin 0.145 0.064 NA
 PDR 0.172 0.024 NA
 CV-RR −0.142 0.075 −0.161 0.034
 HbA1c 0.135 0.076
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of visceral adiposity. Previous studies assessed the inter-
action of adiposity with the association between hyper-
tension and CVD using BMI or WC [7, 8, 48]. Thus, to 
the best our knowledge, this study is the first to investi-
gate the interaction of visceral adiposity directly meas-
ured and blood pressure both with arterial stiffness and 
albuminuria. This study has a couple of limitations that 
should be mentioned. First, it has recently been reported 
that absolute loss of visceral fat mass may play a major 
role in resolution of diabetes following bariatric surgery, 
regardless of the amount of weight loss [49], suggesting 
the importance of prospectively evaluating the change in 
visceral adiposity to investigate the association between 
cardio-metabolic risks including blood pressure and 
organ damage such as arterial stiffening and albuminu-
ria; however, it is impossible to infer causality because 
of its cross-sectional design. Second, population in this 
study was ethnically and socially homogeneous, because 
this study was hospital-based; therefore, generalization 
of our findings might be limited. Third, we were unable 
to obtain information on renin-angiotensin-aldosterone 
system and sympathetic activity. Fourth, we were una-
ble to obtain any information on diet including vitamin 
A which may reduce visceral fat [50]. Finally, it is to be 
elucidated whether the association of blood pressure 
with arterial stiffness and albuminuria could be mediated 
by visceral adiposity in populations other than diabetic 
patients.
Conclusion
The effect of increased blood pressure on arterial stiffness 
is almost similar in type 2 diabetic patients with both 
low and high visceral adiposity, while its association with 
albuminuria is stronger in the latter.
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